# Giorgio V. Scagliotti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/giorgio-v-scagliotti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 51,488 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 92 |
| i10-index | 357 |
| Last Known Institution | Ospedale San Luigi Gonzaga |
| OpenAlex ID | https://openalex.org/A5079802303 |
| ORCID iD | https://orcid.org/0000-0001-6646-958X |
| Works | 1,044 |

## Researcher papers

Showing 12 of 17.

- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [Lung cancer: current therapies and new targeted treatments](https://scholariq.org/papers/lung-cancer-current-therapies-and-new-targeted-treatments/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group](https://scholariq.org/papers/lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-lace-collaborative/)
- [The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015](https://scholariq.org/papers/the-2021-who-classification-of-lung-tumors-impact-of-advances-since-2015/)
- [Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC](https://scholariq.org/papers/liquid-biopsy-for-advanced-non-small-cell-lung-cancer-nsclc-a-statement-paper/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [Adjuvant chemotherapy for resected early-stage non-small cell lung cancer](https://scholariq.org/papers/adjuvant-chemotherapy-for-resected-early-stage-non-small-cell-lung-cancer/)
- [Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase](https://scholariq.org/papers/squamous-cell-carcinoma-of-the-lung-compared-with-other-histotypes-shows-higher/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Ospedale San Luigi Gonzaga](https://scholariq.org/institutions/ospedale-san-luigi-gonzaga/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.